{"entity":{"id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","aka":[],"tldr":"A phase 2/3 trial of tirapazamine in hepatocellular carcinoma, run by Zhejiang Raygene Pharmaceuticals Co., Ltd, now recruiting.","summary":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. is a phase 2/3 interventional study registered as NCT06844357 by Zhejiang Raygene Pharmaceuticals Co., Ltd, with 300 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-04-01. Interventions recorded: tirapazamine, Transarterial Embolization (TAE) and TACE.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06844357","url":"https://clinicaltrials.gov/study/NCT06844357"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06844357","phase":"2/3","setting":"A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","enrolled":300,"outcomes":[]},"route":"/trials/nct06844357/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}